Dalei Chen, PhD

  • 2Articles
  • 13.7KReads1
  • 2014–2023Active
  • 9Collaborators
  • 56Citations2

About

Dalei Chen, PhD, is affiliated with Otsuka Pharmaceutical Development & Commercialization Inc. in Princeton, New Jersey. Chen has published research on major depressive disorder (MDD), focusing on treatments such as brexpiprazole and vilazodone, as well as associated metabolic parameters and body weight changes. Chen's work spans clinical studies evaluating efficacy and safety in depression management. Frequent collaborators include Carl Gommoll, Catherine Weiss, Harry A. Croft, John W. Newcomer, and Maju Mathews.

Publications

JCP
Brexpiprazole in Patients With MDD and Prediabetes
Original Research

Brexpiprazole in Patients With MDD and Prediabetes

August 28, 2023

Some atypical antipsychotics, while efficacious as adjunctive treatments in major depressive disorder (MDD), can lead to adverse effects and weight gain. Adjunctive brexpiprazole had a limited impact on metabolic...
, , , et al
JCP
Original Research

Efficacy and Safety of Vilazodone in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial

November 24, 2014

, , , et al

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Ketamine and Psychedelics

Listen to the Podcast
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe